-
1 week ago | 
medscape.com | Susan Ruel
TOPLINE:A novel, single-use on-body injector (OBI) for isatuximab in multiple myeloma is noninferior to the standard intravenous (IV) formulation in efficacy and pharmacokinetics and has no unexpected safety signals. METHODOLOGY:IRAKLIA is an ongoing study of administration methods of isatuximab as part of a triplet regimen that includes pomalidomide and dexamethasone, commonly used to treat people with relapsed or refractory multiple myeloma.
-
1 month ago | 
news-decoder.com | Susan Ruel
We seem to be leaping ahead in cancer prevention and treatment. But will that be only for those who can pay? A doctor prepares a cervical exam.
-
Feb 13, 2025 | 
univadis.es | Susan Ruel
Editado por la Dra. Susan RuelCONCLUSIÓN PRÁCTICAAgregar daratumumab al tratamiento de mantenimiento con lenalidomida después del trasplante en los pacientes con mieloma múltiple triplica la tasa de conversión de enfermedad residual mínima a negativa al 50,5 % frente al 18,8 % con lenalidomida sola. Con el tratamiento combinado se reduce el riesgo de progresión en un 47 % y se logran tasas estimadas de supervivencia libre de progresión a 30 meses del 82,7 % frente al 66,4 % con lenalidomida sola.
-
Jan 23, 2025 | 
mdedge.com | Susan Ruel
TOPLINE:The analysis of 11,427 US Deparment of Veterans Affairs (VA) hospital patients with multiple myeloma (MM) reveals that lymphopenia affects 53% of patients at diagnosis. The median overall survival was 2.7 years in patients with severely low absolute lymphocyte count vs 4.2 years in those with normal counts.
-
Jan 16, 2025 | 
mdedge.com | Susan Ruel
TOPLINE:In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory drugs achieved an overall response rate of 56.2% and median progression-free survival of 11 months. Longer initial therapy duration and greater time gap between treatments were associated with superior outcomes.
-
Jan 16, 2025 | 
mdedge.com | Susan Ruel
TOPLINE:CD37, a surface protein present on most acute myeloid leukemia (AML) blasts, demonstrates unique internalization properties that enable targeted drug delivery with minimal impact on normal blood cells. Anti-CD37 antibody-drug conjugate (ADC) shows specific cytotoxicity to AML blasts while preserving normal hematopoietic stem cells.
-
Jan 8, 2025 | 
mdedge.com | Susan Ruel
TOPLINE:Glucarpidase treatment in patients with methotrexate-associated acute kidney injury is linked to 2.7 times higher odds of kidney recovery and faster recovery time. The enzyme also reduces the risk for grade ≥ 2 neutropenia and transaminitis by half vs no glucarpidase treatment. METHODOLOGY:Researchers conducted a multicenter cohort study involving 708 adults with methotrexate-associated acute kidney injury from 28 cancer centers across the United States.
-
Nov 13, 2024 | 
mdedge.com | Susan Ruel
TOPLINE:Atrial arrhythmias were found in 26% of patients with sickle cell disease (SCD), with a significant association with stroke history. Early detection and treatment of atrial arrhythmias may help prevent strokes in this population. METHODOLOGY:A total of 130 adult patients with SCD were included in the DREPACOEUR prospective registry from November 2018 to November 2022.
-
Nov 12, 2024 | 
medscape.com | Susan Ruel
TOPLINE: Atrial arrhythmias were found in 26% of patients with sickle cell disease (SCD), with a significant association with stroke history. Early detection and treatment of atrial arrhythmias may help prevent strokes in this population. METHODOLOGY:A total of 130 adult patients with SCD were included in the DREPACOEUR prospective registry from November 2018 to November 2022.
-
Nov 8, 2024 | 
mdedge.com | Susan Ruel
TOPLINE:Venetoclax-obinutuzumab combination therapy for untreated chronic lymphocytic leukemia (CLL) shows a 6-year progression-free survival (PFS) rate of 53%. The time-to-next-treatment (TTNT) rate is 65%, with improved quality of life reported by patients. METHODOLOGY:A total of 432 patients with previously untreated CLL and coexisting conditions were enrolled in the study.
